led by experts at SPARTINA BIOTECHNOLOGIES
Introducing Celerna™
RNA Interference Technology
Celerna™ is a single-celled system for the production, packaging and targeted delivery of therapeutic RNAs.

ABOUT SPARTINA BIOTECHNOLOGIES
Disrupting The RNA Therapeutics Industry
Spartina Biotechnologies is an early-stage biotech company that is developing and implementing a new platform, Celerna™, for the precision delivery of RNA molecules to specific cells and organs to stop the spread of viruses.
Natural RNAi Technology
Natural-like RNA molecules are delivered to the cells that viruses are able to infect, destroying the virus’s RNA.
Blocking Further Replication
This is done without affecting the human gene’s RNA, and blocks further replication and spread of the virus.
Once developed, the Celerna™ platform can be used for broad application in the treatment of:
- Cancers
- Neurogenerative and inflammatory pathological conditions
- Regenerative medicine
- Rapid-deployed treatment for emerging viruses

ABOUT SPARTINA BIOTECHNOLOGIES
Disrupting The RNA Therapeutics Industry
Spartina Biotechnologies is an early-stage biotech company that is developing and implementing a new platform, Celerna™, for the precision delivery of RNA molecules to specific cells and organs to stop the spread of viruses.
Natural RNAi Technology
Natural-like RNA molecules are delivered to the cells that viruses are able to infect, destroying the virus’s RNA.
Blocking Further Replication
This is done without affecting the human gene’s RNA, and blocks further replication and spread of the virus.
Once developed, the Celerna™ platform can be used for broad application in the treatment of:
- Cancers
- Neurogenerative and inflammatory pathological conditions
- Regenerative medicine
- Rapid-deployed treatment for emerging viruses
THE Celerna™ PLATFORM
Our First Application:
COVID-19
To this day, COVID-19 remains a global medical priority. Spartina Biotechnologies is developing the exosomes-based RNA delivery system for treatment of SARS-CoV2 infection. The Celerna™ system will deliver RNA molecules to all cells susceptible to SARS-CoV-2 infection and destroy the virus’s RNA, blocking further replication, and spread of the virus.

THE Celerna™ PLATFORM
Our First Application:
COVID-19
To this day, COVID-19 remains a global medical priority. Spartina Biotechnologies is developing the exosomes-based RNA delivery system for treatment of SARS-CoV-2 infection. The Celerna™ system will deliver RNA molecules to all cells susceptible to SARS-CoV-2 infection and destroy the virus’s RNA, blocking further replication, and spread of the virus.
